Comparative Pharmacology
Head-to-head clinical analysis: CAPREOMYCIN SULFATE versus MYAMBUTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPREOMYCIN SULFATE versus MYAMBUTOL.
CAPREOMYCIN SULFATE vs MYAMBUTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting translation initiation. Also alters membrane permeability.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life: 24-40 hours (prolonged in renal impairment; anuria may extend to 96-120 hours).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
Primarily renal (80-90% as unchanged drug via glomerular filtration). Biliary/fecal elimination: <1%.
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent